Literature DB >> 18334920

Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.

Sierk Haenisch1, Karen May, Danilo Wegner, Amke Caliebe, Ingolf Cascorbi, Werner Siegmund.   

Abstract

OBJECTIVES: To evaluate whether ABCC2 gene polymorphisms are associated with expression and/or function of the efflux pump.
METHODS: We investigated the allele frequency of ABCC2 -24C>T, -23G>A, c.1249G>A, c.1446C>G, c.1457C>T, c.2302C>T, c.2366C>T, c.3542G>T, c.3561G>A, c.3563T>A, c.3972C>T, c.4348G>A, and 4544G>A in 374 nonrelated German healthy volunteers and determined the impact on duodenal mRNA and protein content of ABCC2. For functional analysis, the disposition of intravenously (30 mg) and orally administered talinolol (100 mg) was measured among 31 individuals. Moreover, the effects of rifampicin-type induction (600 mg, 8 days) of duodenal ABCC2 were quantified in 22 participants with regard to genetic polymorphisms.
RESULTS: The allele frequencies were 18.3% (-24T), 21.1% (1249A), 1.4% (1446G), 0.1% (3542T), 4.5% (3563A), 34.2% (3972T), and 4.4% (4544A); carriers of -23G>A, 1457C>T, 2302C>T, 2366C>T, 3561G>A, and 4348G>A were not identified. The -24T allele was in strong linkage with 3972T, and 3563A with 4544A, whereas 1249A was weakly linked with other variant alleles. None of the single nucleotide polymorphisms investigated influenced significantly intestinal ABCC2 mRNA and protein content. The variant ABCC2 1249G>A (V417I), however, was associated with lower oral bioavailability (P=0.001), and increased residual clearance of intravenous talinolol (P=0.021). Intestinal ABCC2 mRNA and protein expression were upregulated by rifampicin treatment, a genetic influence could be detected in only four cases heterozygote for 3563T>A or 4544G>A.
CONCLUSION: The 1249G>A (V417I) polymorphism is obviously associated with higher activity of the intestinal transporter.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334920     DOI: 10.1097/FPC.0b013e3282f974b7

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  24 in total

Review 1.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Authors:  Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

2.  ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children.

Authors:  Raja Venkatasubramanian; Tsuyoshi Fukuda; Jing Niu; Tomoyuki Mizuno; Vidya Chidambaran; Alexander A Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2014-07       Impact factor: 2.533

3.  In Vitro Transport Activity and Trafficking of MRP2/ABCC2 Polymorphic Variants.

Authors:  Xia Wen; Melanie S Joy; Lauren M Aleksunes
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

4.  Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.

Authors:  J A Sprowl; V Gregorc; C Lazzari; R H Mathijssen; W J Loos; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

Review 5.  Mass spectrometry-based targeted proteomics as a tool to elucidate the expression and function of intestinal drug transporters.

Authors:  Stefan Oswald; Christian Gröer; Marek Drozdzik; Werner Siegmund
Journal:  AAPS J       Date:  2013-08-28       Impact factor: 4.009

6.  Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.

Authors:  Chunqiao Tian; Christine B Ambrosone; Kathleen M Darcy; Thomas C Krivak; Deborah K Armstrong; Michael A Bookman; Warren Davis; Hua Zhao; Kirsten Moysich; Holly Gallion; Julie A DeLoia
Journal:  Gynecol Oncol       Date:  2011-11-21       Impact factor: 5.482

7.  Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters.

Authors:  Vera Kim; Thijs van der Wal; Miriam Yumie Nishi; Luciana Ribeiro Montenegro; Flair Jose Carrilho; Yujin Hoshida; Suzane Kioko Ono
Journal:  Pharmacogenomics       Date:  2020-06-03       Impact factor: 2.533

8.  Exploring the Carbamazepine Interaction with Human Pregnane X Receptor and Effect on ABCC2 Using in Vitro and in Silico Approach.

Authors:  Gurpreet K Grewal; Khuraijam D Singh; Neha Kanojia; Chitra Rawat; Samiksha Kukal; Ajay Jajodia; Anshika Singhal; Richa Misra; Selvaraman Nagamani; Karthikeyan Muthusamy; Ritushree Kukreti
Journal:  Pharm Res       Date:  2017-04-21       Impact factor: 4.200

9.  Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.

Authors:  Isabelle Benz-de Bretagne; Noël Zahr; Amélie Le Gouge; Jean-Sébastien Hulot; Caroline Houillier; Khe Hoang-Xuan; Emmanuel Gyan; Séverine Lissandre; Sylvain Choquet; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

10.  Association of CYP2C9*2 with bosentan-induced liver injury.

Authors:  S M Markova; T De Marco; N Bendjilali; E A Kobashigawa; J Mefford; J Sodhi; H Le; C Zhang; J Halladay; A E Rettie; C Khojasteh; D McGlothlin; A H B Wu; W-C Hsueh; J S Witte; J B Schwartz; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2013-07-17       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.